PRE logo

Prenetics Global Limited Stock Price

NasdaqGM:PRE Community·US$340.9m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

PRE Share Price Performance

US$21.82
14.49 (197.68%)
US$34.20
Fair Value
US$21.82
14.49 (197.68%)
36.2% undervalued intrinsic discount
US$34.20
Fair Value
Price US$21.82
AnalystConsensusTarget US$34.20

PRE Community Narratives

·
Fair Value US$34.2 36.2% undervalued intrinsic discount

Bitcoin Treasury And Global Longevity Demand Will Drive Future Health Platform Expansion

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

PRE logo

PRE: Inter Miami Partnership Will Drive Future Revenue And Brand Upside

Fair Value: US$34.2 36.2% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential with excellent balance sheet.

2 Risks
3 Rewards

Prenetics Global Limited Key Details

US$154.6m

Revenue

US$65.3m

Cost of Revenue

US$89.3m

Gross Profit

US$145.3m

Other Expenses

-US$56.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-3.32
57.77%
-36.21%
0%
View Full Analysis

About PRE

Founded
2014
Employees
98
CEO
Sheng Wu Yeung
WebsiteView website
www.prenetics.com

Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Recent PRE News & Updates

Seeking Alpha 12h

Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth

Summary Prenetics Global Limited has achieved explosive growth, reaching 140,000 subscriptions in 20 months, driven by its IM8 supplement and AI-powered marketing. One of the keys to this growth is its marketing mastery, using A/B and multivariate testing to quickly identify the most effective advertising messages. A unique deal with General Catalyst enables PRE to finance up to 70% of customer acquisition costs without equity dilution or debt, amplifying marketing leverage. I maintain a Strong Buy rating, targeting $37.00 per share, reflecting PRE's robust growth, transition to profitability, and superior marketing execution. Read the full article on Seeking Alpha

Recent updates

No updates